Matches in SemOpenAlex for { <https://semopenalex.org/work/W2617201162> ?p ?o ?g. }
- W2617201162 endingPage "1342" @default.
- W2617201162 startingPage "1331" @default.
- W2617201162 abstract "Although extranodal NK/T cell lymphoma (ENKTCL) is consistently associated with Epstein-Barr virus (EBV) infection, the manifestation and prognostic value of serum EBV antibodies still remain unknown. One hundred and forty-one patients with ENKTCL were evaluated for serum EBV EA-IgA and VCA-IgA antibodies levels in the past 24 years in our institution. Their correlation with clinicopathological features, plasma EBV DNA load, and patients' outcomes was analyzed. EBV EA-IgA ≥1:10 and VCA-IgA ≥1:160 were found in 18.4 and 16.3% of patients, respectively. They correlated with adverse ENKTCL profile and inferior overall survival (OS) and progression-free survival (PFS). EA-IgA ≥1:10 was an independent prognostic factor on OS (RR = 2.276, p = 0.008) and associated with lower complete response (CR) rate (34.8 vs 70.6%, p = 0.001) and higher relapse rate in CR patients (62.5 vs 34.7%, p = 0.016). In subgroup analysis, both EA-IgA ≥1:10 and VCA-IgA ≥1:160 significantly correlated with inferior OS and PFS in patients with stage I/II, IPI score 0-1, plasma EBV DNA (+), and CR. Patients with plasma EBV DNA (+) and EA-IgA ≥1:10 (or VCA-IgA ≥1:160) had significantly shorter periods of OS and PFS in comparison with other corresponding groups. Elevated serum EBV EA-IgA and VCA-IgA levels were related to adverse ENKTCL profile and correlated with poor treatment response, early relapse, and poor prognosis in patients with ENKTCL. These findings provide convincing evidence for the use of serum EBV EA-IgA and VCA-IgA antibodies for risk group stratification and prognostic prediction in ENKTCL." @default.
- W2617201162 created "2017-06-05" @default.
- W2617201162 creator A5002661071 @default.
- W2617201162 creator A5005360514 @default.
- W2617201162 creator A5014307249 @default.
- W2617201162 creator A5060820735 @default.
- W2617201162 creator A5070346853 @default.
- W2617201162 creator A5081401106 @default.
- W2617201162 creator A5087356851 @default.
- W2617201162 date "2017-05-27" @default.
- W2617201162 modified "2023-10-10" @default.
- W2617201162 title "Serum EBV EA-IgA and VCA-IgA antibodies can be used for risk group stratification and prognostic prediction in extranodal NK/T cell lymphoma: 24-year experience at a single institution" @default.
- W2617201162 cites W1774597556 @default.
- W2617201162 cites W1844382883 @default.
- W2617201162 cites W1973564365 @default.
- W2617201162 cites W1977496450 @default.
- W2617201162 cites W1977867725 @default.
- W2617201162 cites W1982514699 @default.
- W2617201162 cites W2008325653 @default.
- W2617201162 cites W2021286810 @default.
- W2617201162 cites W2024637605 @default.
- W2617201162 cites W2026540048 @default.
- W2617201162 cites W2031721011 @default.
- W2617201162 cites W2038035645 @default.
- W2617201162 cites W2049422822 @default.
- W2617201162 cites W2053108666 @default.
- W2617201162 cites W2064514024 @default.
- W2617201162 cites W2076257589 @default.
- W2617201162 cites W2101879498 @default.
- W2617201162 cites W2104226988 @default.
- W2617201162 cites W2109069246 @default.
- W2617201162 cites W2134228182 @default.
- W2617201162 cites W2134315181 @default.
- W2617201162 cites W2145638148 @default.
- W2617201162 cites W2151445064 @default.
- W2617201162 cites W2154269623 @default.
- W2617201162 cites W2154913537 @default.
- W2617201162 cites W2167179373 @default.
- W2617201162 cites W2170467044 @default.
- W2617201162 cites W2411576907 @default.
- W2617201162 cites W2416844197 @default.
- W2617201162 cites W2508677410 @default.
- W2617201162 cites W2581810577 @default.
- W2617201162 cites W4235735156 @default.
- W2617201162 doi "https://doi.org/10.1007/s00277-017-3013-y" @default.
- W2617201162 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/5486802" @default.
- W2617201162 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/28550598" @default.
- W2617201162 hasPublicationYear "2017" @default.
- W2617201162 type Work @default.
- W2617201162 sameAs 2617201162 @default.
- W2617201162 citedByCount "11" @default.
- W2617201162 countsByYear W26172011622018 @default.
- W2617201162 countsByYear W26172011622019 @default.
- W2617201162 countsByYear W26172011622020 @default.
- W2617201162 countsByYear W26172011622021 @default.
- W2617201162 countsByYear W26172011622022 @default.
- W2617201162 countsByYear W26172011622023 @default.
- W2617201162 crossrefType "journal-article" @default.
- W2617201162 hasAuthorship W2617201162A5002661071 @default.
- W2617201162 hasAuthorship W2617201162A5005360514 @default.
- W2617201162 hasAuthorship W2617201162A5014307249 @default.
- W2617201162 hasAuthorship W2617201162A5060820735 @default.
- W2617201162 hasAuthorship W2617201162A5070346853 @default.
- W2617201162 hasAuthorship W2617201162A5081401106 @default.
- W2617201162 hasAuthorship W2617201162A5087356851 @default.
- W2617201162 hasBestOaLocation W26172011621 @default.
- W2617201162 hasConcept C126322002 @default.
- W2617201162 hasConcept C159654299 @default.
- W2617201162 hasConcept C194409129 @default.
- W2617201162 hasConcept C203014093 @default.
- W2617201162 hasConcept C2522874641 @default.
- W2617201162 hasConcept C2779102806 @default.
- W2617201162 hasConcept C2779338263 @default.
- W2617201162 hasConcept C2780898057 @default.
- W2617201162 hasConcept C2781375147 @default.
- W2617201162 hasConcept C71924100 @default.
- W2617201162 hasConcept C90924648 @default.
- W2617201162 hasConceptScore W2617201162C126322002 @default.
- W2617201162 hasConceptScore W2617201162C159654299 @default.
- W2617201162 hasConceptScore W2617201162C194409129 @default.
- W2617201162 hasConceptScore W2617201162C203014093 @default.
- W2617201162 hasConceptScore W2617201162C2522874641 @default.
- W2617201162 hasConceptScore W2617201162C2779102806 @default.
- W2617201162 hasConceptScore W2617201162C2779338263 @default.
- W2617201162 hasConceptScore W2617201162C2780898057 @default.
- W2617201162 hasConceptScore W2617201162C2781375147 @default.
- W2617201162 hasConceptScore W2617201162C71924100 @default.
- W2617201162 hasConceptScore W2617201162C90924648 @default.
- W2617201162 hasIssue "8" @default.
- W2617201162 hasLocation W26172011621 @default.
- W2617201162 hasLocation W26172011622 @default.
- W2617201162 hasLocation W26172011623 @default.
- W2617201162 hasLocation W26172011624 @default.
- W2617201162 hasOpenAccess W2617201162 @default.
- W2617201162 hasPrimaryLocation W26172011621 @default.
- W2617201162 hasRelatedWork W2000763528 @default.
- W2617201162 hasRelatedWork W2030837876 @default.
- W2617201162 hasRelatedWork W2039328786 @default.